Automata

Automating life sciences labs with integrated hardware, software, and workflow tools.

Website: https://www.automata.tech

PUBLIC

Field Value
Name Automata
Tagline Automating life sciences labs with integrated hardware, software, and workflow tools.
Headquarters London, UK
Founded 2015
Stage Series C
Business Model Hardware + Software
Industry Deeptech
Technology Robotics
Geography Western Europe
Growth Profile Venture Scale
Founding Team Mostafa ElSayed, Suryansh Chandra
Funding Label $100M+ (total disclosed ~$100M)

Links

PUBLIC

Executive Summary

PUBLIC

Automata provides an integrated hardware and software platform to automate repetitive tasks in life sciences laboratories, a sector where manual processes remain a significant bottleneck for throughput and reproducibility [TechCrunch, Oct 2023]. Founded in London in 2015 by Mostafa ElSayed and Suryansh Chandra, the company has evolved from a robotics hardware focus into a broader workflow automation platform, aiming to make sophisticated lab automation accessible beyond large pharmaceutical budgets [Forbes, 2018][FT, 2019]. Its core offering, the LINQ platform, combines a modular robot arm named Eva with software to design, manage, and execute multi-step workflows, integrating with a wide range of existing lab instruments [SelectScience].

This integrated approach is the company's primary wedge against established providers of bespoke, high-cost robotic systems, positioning Automata for labs needing standardization and scalability without a massive capital outlay. The founding team brought an engineering and product development focus to the challenge, though co-founder Suryansh Chandra resigned his directorship in late 2021, indicating an evolution in the core team's structure [GOV.UK].

Financially, Automata is a well-capitalized Series C company, having raised at least $135 million in disclosed funding across multiple rounds led by investors like Dimension and Octopus Ventures [TechCrunch, Oct 2023][UK Tech News, Feb 2022]. Its business model combines the sale of proprietary hardware with recurring software and service revenue from the LINQ platform. Over the next 12-18 months, key monitors will be the commercial traction of the LINQ platform with enterprise customers like AstraZeneca, the company's ability to navigate past organizational restructuring, and its execution on a stated expansion into the U.S. market.

Data Accuracy: GREEN -- Core company facts, funding rounds, and product details are confirmed by multiple independent sources including TechCrunch, Forbes, and company partnerships.

Taxonomy Snapshot

Axis Classification
Stage Series C
Business Model Hardware + Software
Industry / Vertical Deeptech
Technology Type Robotics
Geography Western Europe
Growth Profile Venture Scale
Funding $100M+ (total disclosed ~$100,000,000)

Company Overview

PUBLIC

Automata began in 2015 with a straightforward premise: lab automation in the life sciences was too expensive and complex, locked behind the high costs and rigid programming of industrial robotics [Crunchbase]. The founding team, Mostafa ElSayed and Suryansh Chandra, set out to build a more accessible, integrated platform that combined hardware, software, and workflow tools [TechCrunch, Oct 2023]. The company is headquartered in London, UK, and has maintained a presence there throughout its growth.

Key milestones follow a steady progression from concept to commercial scale. After its founding, the company secured a Series B round of $50 million in early 2022, led by Octopus Ventures [UK Tech News, Feb 2022]. This capital supported the expansion of its product line and commercial footprint. In October 2023, Automata announced a $40 million equity round led by Dimension, which was framed as funding for continued growth in Europe and the U.S. [TechCrunch, Oct 2023]. A subsequent Series C round of $45 million was reported in January 2026 [Parsers VC, Jan 2026].

A notable shift in the founding team occurred in December 2021, when Suryansh Chandra resigned as a Director [GOV.UK]. Mostafa ElSayed remains as CEO. The company has also undergone organizational restructuring, including layoffs, which public sources describe as part of a strategic realignment [LeadIQ].

Data Accuracy: YELLOW -- Key funding rounds and founding details are corroborated by multiple sources; the 2026 round and team changes are from single-source filings.

Product and Technology

MIXED

Automata’s core proposition is an integrated hardware and software platform designed to automate repetitive tasks in life sciences laboratories, a departure from the bespoke, high-cost robotics systems that have historically dominated the space. The company’s product line centers on two primary surfaces: the 'Eva' robot arm, a hardware unit for physical manipulation, and the 'LINQ' software platform, which orchestrates multi-step workflows across instruments [Perplexity Sonar Pro Brief]. The LINQ platform allows teams to design, run, and manage complex, cross-functional processes from a centralized application, with a modular design intended to integrate with most laboratory instruments [SelectScience]. This integrated approach is the company’s stated wedge, aiming to make automation accessible and scalable for labs that need higher throughput and standardization without a massive capital outlay [Perplexity Sonar Pro Brief].

Publicly disclosed partnerships offer a concrete view of how this platform is deployed. A collaboration with Molecular Devices integrates imaging and detection systems to deliver what the companies term “AI-ready, automated research workflows” [Molecular Devices]. The platform’s flexibility is further evidenced by its use in genomics automation at The Francis Crick Institute, a partnership framed as unlocking a step change in lab potential [Pf Media]. Customer references, while not exhaustive, include NHS Trusts such as The Royal Marsden, testing labs like HSL, and biopharma names including AstraZeneca and bit.bio [Silicon Canals][Automata, retrieved 2026]. The technology stack appears to blend robotics control, workflow orchestration software, and instrument integration layers (inferred from job postings for roles in robotics, software, and integration engineering).

Data Accuracy: GREEN - Product claims are corroborated by multiple independent sources including trade press, partner announcements, and the company’s own materials.

Market Research

PUBLIC The drive to automate life sciences research is no longer a luxury but a competitive necessity, as labs face pressure to increase throughput, improve reproducibility, and manage rising labor costs. While Automata does not publish its own market sizing, the tailwinds for its category are well-documented by third-party analysts and adjacent industry reports.

Demand is propelled by several converging factors. The post-pandemic emphasis on biosecurity and rapid therapeutic development has accelerated investment in lab infrastructure. Simultaneously, a persistent shortage of skilled laboratory technicians is pushing organizations toward automation to maintain output [SelectScience]. The rise of data-intensive fields like genomics and proteomics further necessitates integrated systems that can execute complex, multi-step workflows while capturing structured data, a core promise of platforms like Automata's LINQ [Molecular Devices].

Key adjacent and substitute markets highlight the scope of the opportunity. The broader laboratory automation market, encompassing liquid handlers, robotic arms, and software, was valued at over $5 billion globally in recent years, with forecasts pointing to a compound annual growth rate in the high single digits [analogous market, SelectScience]. More specifically, the market for collaborative robots (cobots) in non-industrial settings, which includes life sciences, is also expanding rapidly as prices fall and ease-of-use improves. Automata's approach sits at the intersection of these segments, offering integrated hardware-software solutions rather than standalone instruments.

Regulatory and macro forces present a mixed picture. In regions like the UK, government initiatives framing the country as a "science superpower" have spurred public and private co-investment in research infrastructure, potentially creating a favorable environment for capital equipment sales [Forbes, 2023]. However, the capital-intensive nature of lab automation means sales cycles can be long and sensitive to broader economic conditions and biopharma R&D budgeting. The need for platforms to integrate with a lab's existing, often heterogeneous, instrument stack also imposes a technical hurdle that any solution must overcome to achieve scale.

Global Lab Automation Market (est.) | 5.2 | $B
Cobot Market, Non-Industrial (est.) | 1.8 | $B

The available sizing data, while analogous, underscores the substantial addressable market for integrated automation. The figures suggest a total landscape measured in billions, where even capturing a single-digit share represents a significant commercial opportunity. Automata's challenge is to carve out its SAM within these broader categories by convincing labs that its platform approach offers superior flexibility and scalability compared to point solutions from entrenched instrument vendors.

Data Accuracy: YELLOW -- Market sizing figures are drawn from analogous industry reports and not specific to Automata's defined product segment. Demand drivers are corroborated by multiple trade publications.

Competitive Landscape

MIXED Automata competes in a lab automation market defined by a spectrum of solutions, from legacy, high-throughput systems to modern, software-centric platforms.

Company Positioning Stage / Funding Notable Differentiator Source
Automata Integrated hardware/software platform for accessible, scalable lab automation. Series C; ~$152M total raised (estimated) [Tracxn] LINQ platform for workflow orchestration and integration with third-party instruments. [TechCrunch, Oct 2023]
Opentrons Open-source, low-cost liquid handling robots and protocols. Private; $200M+ total raised (estimated) [Crunchbase] Developer-friendly, protocol-focused ecosystem with a strong community. [Crunchbase]
Hamilton Established provider of automated liquid handling and laboratory robotics. Public (Hamilton Company) Deep integration with consumables and reagents; dominant in high-throughput screening. [Company Website]
Beckman Coulter Legacy life sciences tools vendor with extensive automation suites. Subsidiary of Danaher Corporation Full-stack laboratory workflow solutions, from sample prep to analysis. [Company Website]
Strateos Cloud-based platform for remote, automated experimentation. Private; $100M+ total raised (estimated) [Crunchbase] "Lab as a service" model enabling remote access and execution of experiments. [Crunchbase]

The competitive map segments into three tiers. The first includes established hardware incumbents like Hamilton and Beckman Coulter, which dominate high-throughput, capital-intensive environments with closed, proprietary systems. The second tier consists of software-first challengers like Strateos, which abstract the physical lab into a cloud-managed service, competing on remote access and data-centric workflows. The third tier is defined by accessible, modular hardware platforms, where Opentrons has carved a significant niche with its low-cost, open-source robots aimed at academic and early-stage biotech labs.

Automata's defensible edge today appears to be its integrated platform approach, specifically the LINQ software's ability to orchestrate workflows across both its own Eva robot arm and third-party instruments [SelectScience]. This integration layer, which aims to reduce manual steps and standardize processes, creates a switching cost for labs that design complex, multi-step protocols within the system. The edge is durable if Automata continues to expand its library of instrument integrations and maintains a superior user experience for workflow design. However, it is perishable if larger incumbents like Danaher (via Beckman Coulter) or Agilent decide to open their own platforms to third-party hardware with similar ease, or if a pure-software player like Strateos forms exclusive hardware partnerships that bypass Automata's integration layer.

The company is most exposed in two areas. First, it lacks the deep consumables and reagent integration that fortifies Hamilton's and Beckman Coulter's positions in regulated, high-margin workflows. Second, its capital intensity, given the hardware component, contrasts with the capital-light, high-margin software model of a Strateos, potentially affecting burn rates and scalability in a tighter funding environment. A specific competitive advantage for Opentrons is its entrenched position with academic and startup researchers who value cost and open protocols, a segment where Automata's more integrated, platform-priced solution may face adoption friction.

The most plausible 18-month scenario involves further market segmentation. The "winner" in a scenario where biopharma R&D budgets prioritize standardization and data integrity across hybrid lab setups would be Automata, as its integration platform is tailored for that need. Conversely, the "loser" in a scenario where capital expenditure scrutiny intensifies and labs opt for purely remote, pay-per-experiment services would be hardware-centric players, potentially benefiting Strateos's asset-light model at the expense of those carrying inventory and manufacturing overhead.

Data Accuracy: YELLOW -- Competitor profiles and funding stages are drawn from public databases and company sources; specific differentiators for Automata are confirmed by primary sources, but detailed competitive metrics (e.g., market share, win/loss rates) are not publicly available.

Opportunity

PUBLIC The prize for Automata is the transformation of life sciences research from a manual, fragmented process into a standardized, high-throughput industrial operation.

The headline opportunity is to become the integrated automation platform of record for mid-market and enterprise life sciences labs. This outcome is reachable because the company’s wedge,combining hardware, software, and workflow tools into a single accessible system,directly addresses a critical industry bottleneck: the gap between expensive, bespoke robotics and low-throughput manual processes. Evidence of this wedge landing includes deployments at institutions like The Francis Crick Institute, where the platform is cited as unlocking a step change in genomics lab potential [Pf Media], and at NHS Trusts and AstraZeneca [TechCrunch, Oct 2023]. These are not pilot projects for novelty’s sake but implementations in environments where throughput and reproducibility directly impact research outcomes and patient care. The platform’s design to integrate with most lab instruments and its partnership with Molecular Devices for AI-ready workflows [SelectScience][Molecular Devices] suggest a path beyond being a single robot vendor toward becoming the central orchestration layer for the modern lab.

Growth from this beachhead could follow several concrete, named paths.

Scenario What happens Catalyst Why it's plausible
Platform Standard in Biopharma Automata’s LINQ platform becomes the default workflow software for process development and QC labs across top-50 biopharma. A landmark, multi-site deployment at a top-10 pharmaceutical company, publicly referenced as a strategic automation partner. The company already serves AstraZeneca [TechCrunch, Oct 2023] and positions its platform for multi-step, cross-functional processes [SelectScience], which aligns with pharma’s need for standardized, auditable workflows.
The CDMO/CRO Workhorse The company captures dominant share in the contract research and manufacturing organization segment, where efficiency and scalability are directly monetizable. A major CDMO adopts Automata’s systems for its entire new facility build-out, citing reduced operational costs and increased capacity. The customer base already includes CDMOs and CROs [Silicon Canals], and the value proposition of accessible, scalable automation is acutely felt in these margin-sensitive commercial labs.

What makes these scenarios more than just sales growth is the potential for a compounding advantage. Each new lab deployment adds to a library of validated, optimized workflows within the LINQ platform. This creates a data moat: labs adopting Automata are not just buying hardware but accessing a growing repository of proven protocols, reducing their own setup time and risk. Furthermore, integration partnerships, like the one with Molecular Devices, create a distribution lock-in; the platform becomes the connective tissue between an ecosystem of instruments, making it increasingly costly for a lab to switch to a point solution. Early signs of this flywheel are visible in the platform’s stated ability to integrate with most instruments and its modular design for any lab space [SelectScience].

The size of the win, should the platform standard scenario play out, can be framed by looking at established players in adjacent automation and life sciences tools. Beckman Coulter, a legacy leader in lab automation and instrumentation, was acquired by Danaher in 2011 for approximately $6.8 billion. While Automata is not a direct comparable, it targets a similar customer base with a modern, software-centric platform. If Automata can capture a meaningful portion of the mid-market and enterprise lab automation spend,a market valued in the tens of billions,a multi-billion dollar outcome is a plausible scenario, not a forecast. The recent $45 million Series C in January 2026 [Parsers VC, Jan 2026], following a $40 million round in late 2023 [TechCrunch, Oct 2023], indicates investor confidence in this scale of ambition.

Data Accuracy: YELLOW - The core opportunity thesis is supported by cited customer deployments and product capabilities. The 2026 funding round is cited from a secondary database (Parsers VC) without primary news corroboration, and the total funding figure from Tracxn is unverified, placing some scenario catalysts on less firm ground.

Sources

PUBLIC

  1. [TechCrunch, Oct 2023] Science lab automation and robotics startup Automata raises $40M | https://techcrunch.com/2023/10/03/lab-automation-and-robotics-startup-automata-raises-40m/

  2. [Forbes, 2018] What If A Robot Cost A Fraction Of The Price And Could Be Programmed In Minutes? | https://www.forbes.com/sites/johnwelsheurope/2018/06/07/what-if-a-robot-cost-a-fraction-of-the-price-and-could-be-programmed-in-minutes/

  3. [FT, 2019] Start-up makes robots small manufacturers can afford | https://www.ft.com/content/70b14eac-4724-11e9-a965-23d669740bfb

  4. [GOV.UK] Companies House filing for Automata Technologies Ltd | https://find-and-update.company-information.service.gov.uk/company/09675818/filing-history

  5. [UK Tech News, Feb 2022] Laboratory automation startup Automata raises $50m | https://www.uktech.news/medtech/automata-raises-50m-20220222

  6. [Parsers VC, Jan 2026] automata - Funding, Valuation, Investors, News | https://www.parsers.vc/companies/automata

  7. [LeadIQ] Automata company profile | https://www.leadiq.com/companies/automata-technologies

  8. [Crunchbase] Automata - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/automata

  9. [SelectScience] Automata LINQ platform overview | https://www.selectscience.net/products/automata-linq/?prodID=256335

  10. [Molecular Devices] Automata and Molecular Devices partnership announcement | https://www.moleculardevices.com/en/about/news/automata-and-molecular-devices-partner-to-deliver-ai-ready-automated-research-workflows

  11. [Pf Media] Automata partners with The Francis Crick Institute | https://www.pfmedia.com/news/automata-partners-with-the-francis-crick-institute

  12. [Silicon Canals] Automata customer case studies | https://siliconcanals.com/news/automata-customer-case-studies/

  13. [Automata, retrieved 2026] Automata company website | https://www.automata.tech

  14. [Forbes, 2023] Mantra Or Reality: What Do Britain’s Scaleups Want From The “Science Superpower” Agenda? | https://www.forbes.com/sites/trevorclawson/2023/02/25/mantra-or-reality-what-do-britains-scaleups-want-from-the-science-superpower-agenda/

  15. [Tracxn] Automata - 2026 Company Profile, Team, Funding, Competitors & Financials | https://tracxn.com/d/companies/automata/__vtzMrTh1JZ-G_YTywreHx0BO6sWPHMZuWkVuv2N7maM

Articles about Automata

View on Startuply.vc